A patient with obesity, prediabetes, and cardiovascular disease would benefit significantly from semaglutide per the SELECT trial (Lincoff et al., New England Journal of Medicine 2023), which showed 20% reduction in major adverse cardiovascular events in non-diabetic patients treated with semaglutide
"It is very difficult to isolate whether psychiatric complications in patients with obesity are associated with their distress about their weight, other life stressors, with a personal or family history of psychiatric illness, or with the effects of trying to lose weight or with having successfully lost it." Wadden told Newsweek that weight loss could result in improvements to physical health and quality of life, and so could improve mental healthbut in a small number of people, weight loss could also have a negative effect
Mitochondrial glutathione neutralizes these free radicals before they damage mitochondrial DNA and membranes
To investigate the functional groups, present in the nanocomposites, Fourier transform infrared spectroscopy (FTIR) was conducted
